Recce Pharmaceuticals Ltd (ASX:RCE) CEO James Graham tells Proactive’s Elisha Newell that the company has secured ethics approval to expand its Phase 1 and 2 UTI studies with lead product RECCE® 327.

The key approval will expand the number of recruits that can participate across world class trial facilities in New South Wales.

Graham says R327 will be administered in around 16 participants as a broad-spectrum anti-infective, with a Phase 2 trial expected to kick off later this year.

“We are pleased to expand our Phase I/II UTI studies with Scientia Clinical Research (NSW) joining present dosing at CMAX (SA),” he told ASX investors on Thursday.

"This now multi-state study expects to expedite our clinical trial progress and address the global health threats posed by UTIs and Urosepsis.”

In essence, Recce’s anti-infectives are designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com